Wittes R E, Wittes J T, Golbey R B
Cancer. 1978 Feb;41(2):415-21. doi: 10.1002/1097-0142(197802)41:2<415::aid-cncr2820410206>3.0.co;2-s.
The activity of three DTIC-containing combinations was compared in a prospective randomized study. Of 101 patients randomized to receive one of the three regimens, 95 received adequate trials. Response rates were as follows: DTIC + cyclophosphamide 7/29 (24%); DTIC + vinblastine 6/34 (18%); DTIC + procarbazine 4/32 (13%). None of these response rates is significantly superior to any of the others. When the activity of the combination is analyzed by sex, DTIC + cyclophosphamide appears more active in females than the other regimens, but the difference is not statistically significant. Response to treatment is associated with significant prolongation of life; the median survival among responders was 11 months, while those who progressed lived a median of 4 months from the start of therapy. Toxicity of all regimens appeared to be about the same; therapy with DTIC + procarbazine was associated with significantly more nausea and vomiting. This study has failed to demonstrate clearly that any of three combinations is superior to any of the others.
在一项前瞻性随机研究中比较了三种含达卡巴嗪（DTIC）组合的活性。在随机接受三种方案之一的101例患者中，95例接受了充分的试验。缓解率如下：DTIC + 环磷酰胺7/29（24%）；DTIC + 长春碱6/34（18%）；DTIC + 丙卡巴肼4/32（13%）。这些缓解率中没有一个显著优于其他任何一个。当按性别分析组合的活性时，DTIC + 环磷酰胺在女性中似乎比其他方案更具活性，但差异无统计学意义。对治疗的反应与生存期的显著延长相关；缓解者的中位生存期为11个月，而疾病进展者从治疗开始起的中位生存期为4个月。所有方案的毒性似乎大致相同；DTIC + 丙卡巴肼治疗相关的恶心和呕吐明显更多。这项研究未能明确证明三种组合中的任何一种优于其他任何一种。
